Peripheral Vascular Devices – Market Insights – Asia Pacific

The Asia Pacific PV device market will grow modestly over the forecast period, driven by the high prevalence of PAD, expanding PAD-related comorbidities, and rising adoption of premium-priced drug-eluting products. Rising procedure volumes for iliac and lower limb indications and the increasing adoption of endovascular techniques over surgical intervention will also fuel market growth, particularly in China. However, cost constraints in publicly funded healthcare systems and limited reimbursement in the region continue to hinder the adoption of premium-priced devices and limit the pace of revenue expansion.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for PV devices in the Asia Pacific region from 2019 through 2033.

Newer technologies will impact the current treatment trend in lower extremities.

What are the newer technologies that will change the treatment trend in lower extremities?

How have these novel technologies impacted market share dynamics in the Asia Pacific region?

The expansion of DES and DCB markets will be driven by new device launches and positive clinical data.

What are some ongoing and completed clinical trials that will contribute to the launch of new DES and DCBs?

Which competitors are likely to enter the DCB market, and which will gain the most market share?

Will the emergence of DCBs have an impact on recently established DES usage?

M&A activities or partnerships involving key competitors may lead to shifts in market shares going forward.

Which acquisitions have occurred, and how will these acquisitions impact competitor performance in the future?

How are competitors leveraging product portfolio acquisitions to expand their product offerings?

Budgetary constraints and insufficient reimbursement in some segments continue to affect the Asia Pacific PV device market.

To what extent the lack of reimbursement will affect the adoption of premium-priced devices such as DES and DCB and procedures such as atherectomy?

How do the reimbursement landscapes differ in the Asia Pacific countries, and what are the recent regulations?

What strategies are the competitors adopting to navigate the challenging cost-constrained Asia Pacific PV device market?